|
|
Article: PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy.
- Article from:
- PR Newswire
- Article date:
- February 3, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Ataluren designated as generic name for PTC124 -
SOUTH PLAINFIELD, N.J., Feb. 3 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that it has successfully completed patient enrollment of its pivotal clinical trial of PTC124 in patients with nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD). Accrual was completed two months ahead of schedule. The company also announced today that PTC124 has been issued the generic name, ataluren.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )
The one-year, multi-center, randomized, double-blind, placebo-controlled study is designed to determine whether ataluren can ...